POSICAINE SP SOLUTION

País: Canadá

Língua: inglês

Origem: Health Canada

Compre agora

Ingredientes ativos:

ARTICAINE HYDROCHLORIDE; EPINEPHRINE (EPINEPHRINE BITARTRATE)

Disponível em:

NOVOCOL PHARMACEUTICAL OF CANADA INC

Código ATC:

N01BB58

DCI (Denominação Comum Internacional):

ARTICAINE, COMBINATIONS

Dosagem:

40MG; 0.01MG

Forma farmacêutica:

SOLUTION

Composição:

ARTICAINE HYDROCHLORIDE 40MG; EPINEPHRINE (EPINEPHRINE BITARTRATE) 0.01MG

Via de administração:

BLOCK/INFILTRATION

Unidades em pacote:

50X1.7ML

Tipo de prescrição:

Ethical

Área terapêutica:

VASOCONSTRICTORS

Resumo do produto:

Active ingredient group (AIG) number: 0226661001; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2012-03-30

Características técnicas

                                Novocol Pharmaceutical of Canada, Inc.
1 of 13
PRODUCT MONOGRAPH
POSICAINE SP
(articaine hydrochloride 4% with 1:100,000 epinephrine (as bitartrate)
INJECTION)
POSICAINE N
(articaine hydrochloride 4% with 1:200,000 epinephrine (as bitartrate)
INJECTION)
Local Anaesthetic for Dental Use
Novocol Pharmaceutical of Canada, Inc.,
Date of Preparation : March 27, 2012
25 Wolseley Court,
Cambridge, Ontario,
Canada
Control No.: 153590
N1R 6X3
Novocol Pharmaceutical of Canada, Inc.
2 of 13
NAME OF DRUG
POSICAINE N
(articaine hydrochloride 4% with 1:200,000 epinephrine (as bitartrate)
INJECTION) POSICAINE SP
(articaine hydrochloride 4% with 1:100,000 epinephrine (as bitartrate)
INJECTION)
THERAPEUTIC CLASSIFACTION
Local Anaesthetic for Dental Use
CLINICAL PHARMACOLOGY
Posicaine is a local anaesthetic that has the reversible effect of
blocking the conduction of
painful sensations. Posicaine decreases nerve conduction by
diminishing the sodium ion
influx during the action potential period. The epinephrine is a
vasoconstrictor added to
Posicaine to slow down the passage into the general circulation and
thus ensure the prolonged
maintenance of an active tissue concentration. The anaesthesia is
obtained rapidly (1 to 3
minutes) and lasts from 45 to 75 minutes per cartridge.
Injected in the mouth by the submucosal route with a solution
containing 1:200,000
epinephrine, articaine reaches the blood concentration peak about 17
minutes after the
injection. The half-life elimination is very short: about 25 minutes.
Articaine is excreted
mainly through the urine with total elimination of 76 % and 89 %
following intramuscular
and intravenous administration, respectively. Two unidentified
metabolites of articaine are
detected in the urine following intramuscular injection accounting for
87 % and 2 % of the
administered dose. No metabolites are detected in the blood following
intravenous
administration.
INDICATIONS AND CLINICAL USE
Posicaine is indicated for infiltration anaesthesia and nerve block
anaesthesia in clinical
dentistry. This 
                                
                                Leia o documento completo
                                
                            

Documentos em outros idiomas

Características técnicas Características técnicas francês 27-03-2012